Pathway enrichment and FDA-approved drug repurposing analysis for the treatment of CTNNB1 Syndrome modeled in an SH-SY5Y cell line. (2025). Translation: The University of Toledo Journal of Medical Sciences, 14(S1). https://doi.org/10.46570/utjms-2025-1507